Latest Period
Q1 2026
Security Snapshot
Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) Institutional Ownership
CUSIP: 137404109
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
113
Shares (Excl. Options)
43,425,726
Price
$4.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.01 par value
- Symbol
- CADL on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 43,425,726
- Total 13F value
- $212,897,065
- Portfolio coverage rank
- 0%
- Share change
- +19,071,986
- Value change
- +$93,310,969
- Number of holders
- 113
- Shares outstanding
- 72,977,477
- SEC-reported price per share
- $8.85
- Insider filing price
- $8.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value is tracked under CUSIP 137404109.
- 113 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 84 to 113 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $133,509,415 to $212,897,065.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 113 institutions filings for Q1 2026.
Security key
137404109
Latest holder period
Q1 2026
13F holders
113
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
CADL full holder history
Candel Therapeutics, Inc. SEC filings
Candel Therapeutics, Inc. company facts
Candel Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 137404109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
CADL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 8.8% | $31,788,989 | 6,422,018 | RTW Investments, LP | 31 Mar 2026 | |||
| FMR LLC | 15% | +63% | $30,582,610 | +$11,592,390 | 6,318,721 | +61% | FMR LLC | 31 Jan 2025 |
| Manning Paul B | 7.9% | $29,997,375 | 5,790,999 | Paul B Manning | 16 Dec 2024 | |||
| BlackRock, Inc. | 4.2% | -20% | $15,091,319 | +$1,079,230 | 3,079,861 | +7.7% | BlackRock, Inc. | 31 Mar 2026 |
| ACORN BIOVENTURES, L.P. | 5.2% | $14,115,428 | 2,580,517 | Anders Hove | 25 Jun 2025 | |||
| BAKER BROS. ADVISORS LP | 5% | -26% | $11,882,723 | -$2,550,075 | 2,455,108 | -18% | Baker Bros. Advisors LP | 31 Mar 2025 |
As of 31 Mar 2026, 113 institutional investors reported holding 43,425,726 shares of Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL). This represents 60% of the company’s total 72,977,477 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
56%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 10,987,017 | +33% | 0% | $53,836,384 |
| RTW INVESTMENTS, LP | 8.8% | 6,422,018 | 0.31% | $31,467,888 | |
| ACORN CAPITAL ADVISORS, LLC | 4.8% | 3,497,948 | +36% | 4.9% | $17,209,904 |
| BlackRock, Inc. | 4.3% | 3,109,042 | +8.6% | 0% | $15,234,307 |
| Saturn V Capital Management LP | 4% | 2,896,588 | 2.6% | $14,193,281 | |
| Portolan Capital Management, LLC | 4% | 2,894,325 | +71% | 0.75% | $14,182,193 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 2,462,757 | 0% | 0% | $12,067,509 |
| Vestal Point Capital, LP | 1.5% | 1,125,000 | 0.15% | $5,512,500 | |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 1,060,086 | 0% | $5,194,421 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,035,435 | +5.9% | 0% | $5,074,684 |
| Halter Ferguson Financial Inc. | 1.2% | 904,051 | +21% | 0.98% | $4,429,848 |
| STATE STREET CORP | 1.1% | 818,558 | +3.3% | 0% | $4,010,934 |
| HEIGHTS CAPITAL MANAGEMENT, INC | 1.1% | 775,000 | 1.1% | $3,797,500 | |
| Sands Capital Alternatives, LLC | 0.56% | 405,837 | 0% | 0.47% | $1,988,601 |
| NORTHERN TRUST CORP | 0.44% | 323,154 | +9.4% | 0% | $1,583,455 |
| VANGUARD FIDUCIARY TRUST CO | 0.38% | 280,451 | 0% | 0% | $1,374,210 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.37% | 268,249 | 0% | 0% | $1,314,420 |
| GOLDMAN SACHS GROUP INC | 0.31% | 227,521 | +250% | 0% | $1,114,853 |
| ExodusPoint Capital Management, LP | 0.31% | 227,468 | 0.01% | $1,114,593 | |
| Ghisallo Capital Management LLC | 0.27% | 200,000 | 0.03% | $980,000 | |
| Kynam Capital Management, LP | 0.27% | 200,000 | 0.06% | $980,000 | |
| Tanager Wealth Management LLP | 0.27% | 198,175 | 0% | 0.09% | $971,058 |
| JANUS HENDERSON GROUP PLC | 0.24% | 171,978 | 0% | $845,272 | |
| Woodline Partners LP | 0.21% | 156,700 | 0% | $767,830 | |
| UBS Group AG | 0.21% | 149,855 | +44% | 0% | $734,290 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 43,425,726 | $212,897,065 | +$93,310,969 | $4.90 | 113 |
| 2025 Q4 | 23,634,025 | $133,509,415 | +$5,752,184 | $5.65 | 84 |
| 2025 Q3 | 22,668,478 | $115,621,483 | -$1,871,335 | $5.10 | 81 |
| 2025 Q2 | 23,037,394 | $116,569,933 | +$8,831,720 | $5.06 | 78 |
| 2025 Q1 | 21,190,126 | $119,726,836 | +$12,537,033 | $5.65 | 82 |
| 2024 Q4 | 17,950,985 | $155,743,026 | +$97,379,454 | $8.68 | 70 |
| 2024 Q3 | 6,693,196 | $46,384,699 | +$3,074,083 | $6.93 | 51 |
| 2024 Q2 | 5,961,761 | $36,964,279 | +$13,959,987 | $6.20 | 45 |
| 2024 Q1 | 3,780,257 | $5,972,529 | -$231,572 | $1.58 | 18 |
| 2023 Q4 | 4,027,160 | $5,919,504 | -$1,196,574 | $1.47 | 21 |
| 2023 Q3 | 5,257,852 | $4,856,205 | -$147,500 | $0.92 | 19 |
| 2023 Q2 | 5,370,044 | $6,766,125 | -$142,743 | $1.26 | 19 |
| 2023 Q1 | 5,478,268 | $7,437,200 | +$69,459 | $1.35 | 20 |
| 2022 Q4 | 5,420,630 | $9,702,154 | -$1,788,500 | $1.79 | 20 |
| 2022 Q3 | 6,080,809 | $19,096,287 | -$834,398 | $3.14 | 22 |
| 2022 Q2 | 6,345,954 | $20,561,000 | -$1,159,878 | $3.24 | 21 |
| 2022 Q1 | 6,674,026 | $33,969,000 | -$1,719,786 | $5.08 | 21 |
| 2021 Q4 | 6,951,728 | $54,359,000 | +$875,765 | $7.82 | 20 |
| 2021 Q3 | 4,884,284 | $52,945,000 | +$44,146,000 | $10.84 | 12 |